Paper21453545
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
Takahashi S. J Hematol Oncol, 2011. Cited by 191 papers, by iCite.
Cite this record
ConductScience Library. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Papers, record 21453545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21453545
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Gene Expression Regulation, Leukemic | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| fms-Like Tyrosine Kinase 3 | Major topic |
| Animals | |
| Humans | |
| Mutation | |
| Signal Transduction | |
| Transcription Factors |
Source PubMed
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12951584 | The role of FLT3 in haematopoietic malignancies. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12951584 | PubMed |
| 2 | 11290608 | Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. | Blood | 2001 | https://conductscience.org/library/papers/11290608 | PubMed |
| 3 | 19448675 | RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. | Oncogene | 2009 | https://conductscience.org/library/papers/19448675 | PubMed |
| 4 | 12670652 | Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. | Bioorg Med Chem | 2003 | https://conductscience.org/library/papers/12670652 | PubMed |
| 5 | 10573574 | Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. | Med Pediatr Oncol | 1999 | https://conductscience.org/library/papers/10573574 | PubMed |
| 6 | 15498859 | Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. | Blood | 2005 | https://conductscience.org/library/papers/15498859 | PubMed |
| 7 | 15718420 | FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. | Blood | 2005 | https://conductscience.org/library/papers/15718420 | PubMed |
| 8 | 19309322 | Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. | Eur J Haematol | 2009 | https://conductscience.org/library/papers/19309322 | PubMed |
| 9 | 10502596 | Acute myeloid leukemia. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10502596 | PubMed |
| 10 | 12663439 | Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. | Blood | 2003 | https://conductscience.org/library/papers/12663439 | PubMed |
| 11 | 20809224 | Targeted signal transduction therapies in myeloid malignancies. | Curr Oncol Rep | 2010 | https://conductscience.org/library/papers/20809224 | PubMed |
| 12 | 20096459 | Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. | Leuk Res | 2010 | https://conductscience.org/library/papers/20096459 | PubMed |
| 13 | 15126317 | In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. | Blood | 2004 | https://conductscience.org/library/papers/15126317 | PubMed |
| 14 | 17655729 | FLT3 inhibition in acute myeloid leukaemia. | Br J Haematol | 2007 | https://conductscience.org/library/papers/17655729 | PubMed |
| 15 | 7630197 | Expression of the flt3 receptor and its ligand on hematopoietic cells. | Leukemia | 1995 | https://conductscience.org/library/papers/7630197 | PubMed |
| 16 | 9454740 | c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. | Blood | 1998 | https://conductscience.org/library/papers/9454740 | PubMed |
| 17 | 7692230 | Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. | Mol Cell Biol | 1993 | https://conductscience.org/library/papers/7692230 | PubMed |
| 18 | 12357354 | Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. | Leukemia | 2002 | https://conductscience.org/library/papers/12357354 | PubMed |
| 19 | 12969963 | FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. | Blood | 2004 | https://conductscience.org/library/papers/12969963 | PubMed |
| 20 | 14630076 | FLT3 mutations are associated with other molecular lesions in AML. | Leuk Res | 2004 | https://conductscience.org/library/papers/14630076 | PubMed |
Cited by138
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42696088 | The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42696088 | PubMed |
| 42434847 | QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. | Future Oncol | 2026 | https://conductscience.org/library/papers/42434847 | PubMed |
| 42346642 | Hormone-Driven Growth Signaling as a Therapeutic Target in Acute Myeloid Leukemia: Implications for Drug-Resistant Disease. | J Pers Med | 2026 | https://conductscience.org/library/papers/42346642 | PubMed |
| 42323414 | SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42323414 | PubMed |
| 42198431 | Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198431 | PubMed |
| 41916299 | Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss. | Cell Rep Methods | 2026 | https://conductscience.org/library/papers/41916299 | PubMed |
| 41899095 | Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899095 | PubMed |
| 41590345 | Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies. | Curr Oncol | 2026 | https://conductscience.org/library/papers/41590345 | PubMed |
| 41463291 | Mitochondrial Dysfunction in Apoptosis-Resistant Acute Myeloid Leukemia Cells During a Sterile Inflammatory Response. | Biomolecules | 2025 | https://conductscience.org/library/papers/41463291 | PubMed |
| 41372872 | New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41372872 | PubMed |
| 41287669 | Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review. | Cureus | 2025 | https://conductscience.org/library/papers/41287669 | PubMed |
| 41228209 | FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228209 | PubMed |
| 41215958 | Understanding the characteristic behaviour of the wild-type and mutant structure of FLT3 protein by computational methods. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/41215958 | PubMed |
| 41095756 | A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41095756 | PubMed |
| 41090755 | Counter-Therapeutic Strategies for Resistance of FLT3 Inhibitors in Acute Myeloid Leukemia. | Cells | 2025 | https://conductscience.org/library/papers/41090755 | PubMed |
| 40748523 | Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/40748523 | PubMed |
| 40464185 | Recent Advances in FLT3-Based Dual Inhibitors: A Promising Strategy for the Treatment of Acute Myeloid Leukemia. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/40464185 | PubMed |
| 40061103 | Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature. | Eur Heart J Case Rep | 2025 | https://conductscience.org/library/papers/40061103 | PubMed |
| 39963240 | Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/39963240 | PubMed |
| 39863894 | Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers. | J Ovarian Res | 2025 | https://conductscience.org/library/papers/39863894 | PubMed |
Genes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21453545
GET https://conductscience.org/api/papers/v1/21453545/references?page=2